Clinical trials: Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease
The OXISITE-ILD study is a prospective, multicenter, observational study designed to evaluate the agreement between finger (digital) and earlobe (auricular) pulse oximetry for measuring oxygen saturation (SpO2) during the…
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis, Connective Tissue Disease-Associated Interstitial Lung Disease
- Trial name
- OXISITE-ILD (NCT07723872)
- Testing
- Dual-site pulse oximetry (finger and earlobe)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital de Granollers
Scleroderma, Systemic, Fibrosis; Skin
Western Sweden Systemic Sclerosis Project
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment…
- Conditions
- Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- WESST (NCT07345052)
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder)
Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography
Lung involvement is one of the most frequent extra articular involvements of rheumatoid arthritis (RA). RA related lung involvement can affect parenchyma, airway, vascular tree and serosa.
- Conditions
- Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), Idiopathic Pulmonary Fibrosis (IPF), Connective Tissue Disease (CTD)
- Trial name
- NCT07174102
- Testing
- High resolution computed tomography
- Where
- 5 sites in Czechia, Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Telomere Biology Disorders, Dyskeratosis Congenita
Nucleoside Therapy in Patients With Telomere Biology Disorders
The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders.
- Conditions
- Telomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson Syndrome
- Trial name
- NCT06817590
- Testing
- deoxycytidine, deoxythymidine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Suneet Agarwal
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with…
- Trial name
- CONQUEST (NCT06195072)
- Testing
- Amlitelimab, BI 1015550 (Nerandomilast)
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Scleroderma Research Foundation, Inc.
Dermatomyositis, Dermatomyositis Sine Myositis
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD).
- Conditions
- Dermatomyositis, Dermatomyositis Sine Myositis, Dermatomyositis With Myopathy, Dermatomyositis With Respiratory Involvement
- Trial name
- NCT07486869
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
NSCLC, NSCLC, Stage I
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease…
- Conditions
- NSCLC, NSCLC, Stage I, NSCLC Stage II, Non Small Cell Lung Cancer
- Trial name
- NCT07323732
- Testing
- BIO 300
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder)
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease
Pulmonary abnormalities are present in up to 60% of patients with early rheumatoid arthritis (RA), and up to 10% of the patients will develop clinical interstitial lung disease (ILD).
- Conditions
- Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), RA, ILD
- Trial name
- PULMORA (NCT04311567)
- Testing
- Tofacitinib, Methotrexate
- Where
- 3 sites in Sweden
- Volunteers
- 3 people
- Sponsor
- Vastra Gotaland Region
Interstitial Lung Disease Due to Systemic Disease
Registry of Autoimmune Interstitial Lung Disease
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma.
- Trial name
- EPIMAR (NCT05365009)
- Testing
- Multidisciplinary aproach
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- EPIMAR registry